Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours

Area of Science:

• Pediatric Endocrinology
• Oncology
• Metabolic Disorders

Background:

• Hypothalamic obesity (HyOb) is a frequent complication in children diagnosed with hypothalamic tumors.
• Patients with HyOb face a potentially elevated mortality risk, often linked to obstructive sleep apnea/hypoventilation.

Purpose of the Study:

• To ascertain predictive factors for mortality in pediatric patients experiencing HyOb.
• To identify key indicators for improved survival outcomes in this vulnerable population.

Main Methods:

• A cohort of twenty children diagnosed with HyOb secondary to hypothalamic tumors was studied.
• Follow-up extended over a minimum of 3 years, with participants under 15 years at diagnosis and receiving short-term glucocorticoid treatment.

Main Results:

• A significant increase in Body Mass Index (BMI) Standard Deviation Score (SDS) was observed within the first 6 months of therapy.
• Mortality risk was notably higher in patients with a BMI SDS increase exceeding 1 after 6 months (RR: 8.4, P<0.05).
• Younger children (age <6 years at diagnosis) and those reaching a maximum BMI SDS ≥3 exhibited substantially higher mortality rates.

Conclusions:

• An escalating BMI SDS after 6 months of therapy emerges as a critical risk factor for HyOb-related mortality.
• Early diagnosis (age <6 years) and achieving a maximum BMI SDS ≥3 are associated with increased mortality, underscoring the need for prompt and intensive obesity management.